Walpar Nutritions Ltd
Incorporated in 2009, Walpar Nutrition Ltd develops and manufactures various pharmaceutical products.[1]
- Market Cap ₹ 38.3 Cr.
- Current Price ₹ 40.8
- High / Low ₹ 53.3 / 37.7
- Stock P/E 16.4
- Book Value ₹ 18.9
- Dividend Yield 0.00 %
- ROCE 16.1 %
- ROE 15.1 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 57.9 days to 42.2 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 11.2% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 6.07 | 26.76 | 35.14 | 62.52 | 71.76 | 75.73 | |
| 5.61 | 25.74 | 31.65 | 57.77 | 66.04 | 69.71 | |
| Operating Profit | 0.46 | 1.02 | 3.49 | 4.75 | 5.72 | 6.02 |
| OPM % | 7.58% | 3.81% | 9.93% | 7.60% | 7.97% | 7.95% |
| 0.00 | 0.02 | 0.32 | 0.22 | 0.27 | 0.09 | |
| Interest | 0.18 | 0.48 | 0.79 | 0.67 | 0.29 | 0.33 |
| Depreciation | 0.12 | 0.28 | 1.91 | 1.81 | 1.82 | 1.94 |
| Profit before tax | 0.16 | 0.28 | 1.11 | 2.49 | 3.88 | 3.84 |
| Tax % | 6.25% | -32.14% | 27.03% | 22.09% | 27.84% | |
| 0.15 | 0.36 | 0.81 | 1.94 | 2.79 | 2.89 | |
| EPS in Rs | 0.22 | 0.42 | 0.65 | 1.68 | 2.47 | 2.48 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 39% |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 81% |
| TTM: | -6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 5% |
| 1 Year: | -18% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 11% |
| Last Year: | 15% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 3.34 | 4.54 | 4.54 | 4.70 | 9.39 | 9.39 |
| Reserves | 1.44 | 6.45 | 7.17 | 9.49 | 7.17 | 8.36 |
| 7.49 | 7.25 | 10.30 | 8.30 | 7.85 | 8.48 | |
| 5.73 | 9.85 | 12.29 | 14.67 | 22.98 | 27.68 | |
| Total Liabilities | 18.00 | 28.09 | 34.30 | 37.16 | 47.39 | 53.91 |
| 1.70 | 2.01 | 10.13 | 10.20 | 10.65 | 11.42 | |
| CWIP | 1.22 | 4.48 | 0.02 | 0.02 | 0.03 | 0.00 |
| Investments | 0.00 | 0.49 | 0.02 | 1.88 | 1.88 | 2.24 |
| 15.08 | 21.11 | 24.13 | 25.06 | 34.83 | 40.25 | |
| Total Assets | 18.00 | 28.09 | 34.30 | 37.16 | 47.39 | 53.91 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| -0.31 | -1.08 | 1.10 | 5.35 | 4.06 | |
| -2.02 | -6.14 | -3.44 | -3.61 | -2.30 | |
| 2.95 | 6.71 | 2.42 | -1.77 | -0.68 | |
| Net Cash Flow | 0.62 | -0.51 | 0.07 | -0.03 | 1.08 |
| Free Cash Flow | -2.17 | -4.92 | -4.14 | 3.48 | 1.78 |
| CFO/OP | -67% | -99% | 34% | 116% | 82% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 430.54 | 124.26 | 129.63 | 78.46 | 107.73 |
| Inventory Days | 369.26 | 103.22 | 128.73 | 67.15 | 67.85 |
| Days Payable | 455.40 | 135.07 | 143.88 | 72.94 | 108.50 |
| Cash Conversion Cycle | 344.41 | 92.41 | 114.48 | 72.67 | 67.07 |
| Working Capital Days | 316.29 | 61.65 | 87.87 | 43.55 | 42.17 |
| ROCE % | 4.85% | 8.78% | 12.75% | 16.08% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Domestic Sales Revenue Rs. in Lakhs |
|
||||
| Employee Benefit Expenses Rs. in Lakhs |
|||||
| Export Sales Revenue Rs. in Lakhs |
|||||
| Trade Receivables Turnover Ratio times |
|||||
Extracted by Screener AI
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
8 April 2026 - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026; no physical shares received for dematerialization.
-
Structural Digital Database
8 April 2026 - Submitted SDD compliance certificate for quarter ended 31 March 2026; no non-compliance observed.
-
Structural Digital Database
8 April 2026 - Submitted FY2025-26 SDD compliance certificate; no non-compliance reported.
-
Trading Window
28 March 2026 - Trading window closed from 1 Apr 2026 until 48 hours after audited results for year/half-year ended 31 Mar 2026.
-
Outcome of Board Meeting
20 March 2026 - Board approved corporate guarantee to SIDBI for Walpar Wellness's Rs.5,64,05,000 term loan (20 Mar 2026).
Business Overview:[1][2]
WNL is in the business of manufacturing and trading of Pharmaceutical, Nutraceutical, Herbal, and Ayurvedic Products. The company has a presence across 42+ countries and has served 650+ clients.